Cian Healthcare Moves Closer to Revival with BSE Share Issuance Approval

Cian Healthcare Limited has received in-principle approval from the BSE for issuing equity shares as part of its resolution plan, a significant move toward its operational revival. The plan, approved by the National Company Law Tribunal (NCLT) on December 18, 2025, involves issuing over 2.37 crore shares to prospective promoters and 12.5 lakh shares to public shareholders.

This development is a crucial step as Cian Healthcare navigates its post-insolvency period. The BSE's approval is a prerequisite for listing the newly issued shares, signaling progress towards operational normalcy and capital restructuring. It marks a key milestone in the company's journey toward potentially relisting its shares after its Corporate Insolvency Resolution Process (CIRP).

Background on Insolvency

Cian Healthcare was admitted to CIRP by the NCLT Mumbai on June 12, 2024, after an operational creditor filed a claim for unpaid dues totaling ₹1.14 crore. The company successfully concluded its CIRP on February 01, 2026, reaching a settlement of ₹37.30 crore with resolution applicant Mr. Pradeep Kumar Jain. The NCLT's December 18, 2025, order approved the resolution plan, which included significant changes to the company's share structure, such as the cancellation of existing promoter shares and a reduction in public shares to make way for new equity.

Changes Ahead

The company's capital structure will be reshaped by the issuance of new equity shares to both promoters and public shareholders. These new promoter shares will carry equal rights with existing public shares. This BSE approval is vital for fulfilling the resolution plan's conditions, paving the way for these new shares to be listed and for the company to potentially resume public trading.

Potential Risks

The BSE could withdraw its 'in-principle' approval if any information provided is found to be incomplete, incorrect, or misleading, or if the company violates any rules. Cian Healthcare has a history of financial difficulties that led to CIRP, and its auditors issued disclaimer opinions for FY25, citing concerns including pending claim reconciliations and doubts about the company's ability to continue operating. Furthermore, its subsidiary, Dr. Smith's Biotech Private Limited, also underwent CIRP.

Peer Landscape

Cian Healthcare operates within India's broader pharmaceutical sector. Major players like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd. are well-established, with extensive domestic and international operations driven by strong R&D and diverse product portfolios. While these peers focus on innovation and global expansion, Cian Healthcare's immediate objective is stabilization and growth following its restructuring.

Financial Snapshot

For the financial year ended March 31, 2025, Cian Healthcare reported a consolidated revenue decline of 50% to ₹3,079.84 lakhs. The company posted a consolidated net loss of ₹2,597.75 lakhs for FY25. Auditors issued a disclaimer opinion for FY25, highlighting issues such as pending claim reconciliations and doubts about the company's ability to continue operating.

Next Steps to Watch

Investors will be tracking the completion of all compliance requirements and stipulated conditions for share allotment. The formal trading and listing procedures for the newly issued shares on the BSE are also key. Furthermore, the company's operational and financial performance post-restructuring and relisting, along with management's strategy for growth and re-establishing market presence, will be closely monitored.